PLGA-PEG-Maleimide from PolySciTech used in development of targeted nanotherapy against cancer

 

Tumor-specific peptides can be decorated on the outer surface of a nanoparticle formulation and utilized to target the particles towards cancer cells. Researchers at Queen's University Belfast, Cancer Research UK Manchester Institute, and Immunocore Ltd used PLGA-PEG-Mal (Cat# AI020) from PolySciTech division of Akina, Inc. (www.polyscitech.com) to create T-cell receptor targeted nanoparticles to deliver docetaxel to tumors. This research holds promise to provide for treatment against cancer. Read More: McDaid, William J., Nikolai Lissin, Ellen Pollheimer, Michelle Greene, Adam Leach, Peter Smyth, Giovanna Bossi, Daniel Longley, David K. Cole, and Christopher J. Scott. "Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors." Nanoscale 13, no. 35 (2021): 15010-15020. https://pubs.rsc.org/en/content/articlehtml/2021/nr/d1nr04001d

“For effective targeted therapy of cancer with chemotherapy-loaded nanoparticles (NPs), antigens that are selective for cancer cells should be targeted to minimise off-tumour toxicity. Human leukocyte antigens (HLAs) are attractive cancer targets as they can present peptides from tumour-selective proteins on the cell surface, which can be recognised by T cells via T cell receptors (TCRs). In this study, docetaxel-loaded polymeric NPs were conjugated to recombinant affinity-enhanced TCRs to target breast cancer cells presenting a tumour-selective peptide-HLA complex. The TCR-conjugated nanoparticles enabled enhanced delivery of docetaxel and induced cell death through tumour-specific peptide-HLA targeting. These in vitro data demonstrate the potential of targeting tumour-restricted peptide-HLA epitopes using high affinity TCR-conjugated nanoparticles, representing a novel treatment strategy to deliver therapeutic drugs specifically to cancer cells.”